AzaCITIDine - Latest Advances

A Massive Haemothorax Due to Pleural Extramedullary Haematopoiesis in a Patient With Myelodysplastic Syndrome/Myeloproliferative Neoplasm.

Journal: Cureus

Published: December 13, 2025

Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

A preliminary analysis of the efficacy and safety of homoharringtonine, venetoclax, and azacitidine for newly diagnosed acute myeloid leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: December 03, 2025

Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine.

Journal: JCO clinical cancer informatics

Published: December 02, 2025

TMEM91::TAL1 Fusion gene in a middle-aged female with rapid MDS to secondary AML progression: a case report.

Journal: Hematology (Amsterdam, Netherlands)

Published: November 29, 2025

Integrated transcriptomic and methylome analysis reveals retinoic acid pathway activation after decitabine treatment in EBV associated gastric cancer.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Arginine Metabolism Supports De Novo Pyrimidine Biosynthesis to Block DNA Damage and Maintain Epstein-Barr Virus Latency.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML.

Journal: Future oncology (London, England)

Published: November 19, 2025

Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.

Journal: JAMA dermatology

Published: November 19, 2025

ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia.

Journal: Future oncology (London, England)

Published: November 16, 2025

Real-World Study of 21-Day Venetoclax Plus Azacitidine Regimen in the Treatment of Newly Diagnosed Unfit-Acute Myeloid Leukemia

Journal: Zhongguo shi yan xue ye xue za zhi

Published: November 14, 2025

Screening of Anti-Tumor Drugs that Enhance Antigen Presentation of AML Cells with TCR-Like Antibody

Journal: Zhongguo shi yan xue ye xue za zhi

Published: November 14, 2025

Filters

A Massive Haemothorax Due to Pleural Extramedullary Haematopoiesis in a Patient With Myelodysplastic Syndrome/Myeloproliferative Neoplasm.

A Massive Haemothorax Due to Pleural Extramedullary Haematopoiesis in a Patient With Myelodysplastic Syndrome/Myeloproliferative Neoplasm.

Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches.

Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches.

A preliminary analysis of the efficacy and safety of homoharringtonine, venetoclax, and azacitidine for newly diagnosed acute myeloid leukemia

A preliminary analysis of the efficacy and safety of homoharringtonine, venetoclax, and azacitidine for newly diagnosed acute myeloid leukemia

Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine.

Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine.

TMEM91::TAL1 Fusion gene in a middle-aged female with rapid MDS to secondary AML progression: a case report.

TMEM91::TAL1 Fusion gene in a middle-aged female with rapid MDS to secondary AML progression: a case report.

Integrated transcriptomic and methylome analysis reveals retinoic acid pathway activation after decitabine treatment in EBV associated gastric cancer.

Integrated transcriptomic and methylome analysis reveals retinoic acid pathway activation after decitabine treatment in EBV associated gastric cancer.

Arginine Metabolism Supports De Novo Pyrimidine Biosynthesis to Block DNA Damage and Maintain Epstein-Barr Virus Latency.

Arginine Metabolism Supports De Novo Pyrimidine Biosynthesis to Block DNA Damage and Maintain Epstein-Barr Virus Latency.

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML.

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML.

Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.

Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.

ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia.

ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia.

Real-World Study of 21-Day Venetoclax Plus Azacitidine Regimen in the Treatment of Newly Diagnosed Unfit-Acute Myeloid Leukemia

Real-World Study of 21-Day Venetoclax Plus Azacitidine Regimen in the Treatment of Newly Diagnosed Unfit-Acute Myeloid Leukemia

Screening of Anti-Tumor Drugs that Enhance Antigen Presentation of AML Cells with TCR-Like Antibody

Screening of Anti-Tumor Drugs that Enhance Antigen Presentation of AML Cells with TCR-Like Antibody